<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529811</url>
  </required_header>
  <id_info>
    <org_study_id>RBPK1001</org_study_id>
    <nct_id>NCT04529811</nct_id>
  </id_info>
  <brief_title>Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Rifaximin Formulations in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, Randomised, Placebo-Controlled, Single-Ascending Dose and Multiple-Dose with 3 novel&#xD;
      RIFAXIMIN Formulations.&#xD;
&#xD;
      2 phases: Single-Ascending Dose (SAD) Phase and a Multiple-Dose (MD) Phase, Plus optional&#xD;
      open-label, crossover Food Effect (FE) Evaluation&#xD;
&#xD;
      Primary objective: evaluate the safety and tolerability of three novel formulations of&#xD;
      rifaximin in healthy volunteers.&#xD;
&#xD;
      Secondary objective: evaluate the pharmacokinetics (PK) of the novel formulations and to&#xD;
      assess for the presence of exploratory biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Actual">May 9, 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events</measure>
    <time_frame>Up to 18 days</time_frame>
  </primary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Formulation 1 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 1 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 1 Capsules - Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 1 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 1 Capsules - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 1 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 1 Capsules - Max Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 1 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 1 Capsules - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Formulation 1 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 2 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2- Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 2 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2 - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 2 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2 - Max Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 2 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Formulation 2 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3 - Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 3 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3 - Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 3 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3 - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 3 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3 - Max dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin Formulation 3 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Formulation 3 Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin Novel Formulation</intervention_name>
    <description>Rifaximin Novel Formulation</description>
    <arm_group_label>Formulation 1 - Low Dose</arm_group_label>
    <arm_group_label>Formulation 1 Capsules - High Dose</arm_group_label>
    <arm_group_label>Formulation 1 Capsules - Max Dose</arm_group_label>
    <arm_group_label>Formulation 1 Capsules - Mid Dose</arm_group_label>
    <arm_group_label>Formulation 2 - High Dose</arm_group_label>
    <arm_group_label>Formulation 2 - Low Dose</arm_group_label>
    <arm_group_label>Formulation 2 - Max Dose</arm_group_label>
    <arm_group_label>Formulation 2- Mid Dose</arm_group_label>
    <arm_group_label>Formulation 3 - High dose</arm_group_label>
    <arm_group_label>Formulation 3 - Low dose</arm_group_label>
    <arm_group_label>Formulation 3 - Max dose</arm_group_label>
    <arm_group_label>Formulation 3 - Mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Formulation 1 Capsules - Placebo</arm_group_label>
    <arm_group_label>Formulation 2 - Placebo</arm_group_label>
    <arm_group_label>Formulation 3 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has the ability and willingness to sign a written informed consent, is&#xD;
             either male or female aged between 18 and 65 years, inclusive, at the time of informed&#xD;
             consent, is in good general health, and has a body mass index (BMI) at least 18 kg/m2&#xD;
             and at most 34 kg/m2, and a minimum body weight of 45 kg.&#xD;
&#xD;
          -  The participant must have suitable venous access for blood sampling and be able and&#xD;
             willing to complete the study and comply with all study instructions and attend the&#xD;
             necessary visits.&#xD;
&#xD;
          -  A negative pregnancy test is required for all women of child-bearing potential&#xD;
             (WOCBP). WOCBP and men must agree to use highly effective contraception methods from&#xD;
             screening through the end of the study. Follicle stimulating hormone (FSH) testing&#xD;
             will be conducted for post-menopausal women without surgical evidence of sterility&#xD;
             (total hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participant who is pregnant, trying to become pregnant, or breast feeding.&#xD;
&#xD;
          -  Participant with a known or suspected intolerance to rifaximin or the excipients used&#xD;
             in the novel formulations.&#xD;
&#xD;
          -  Participant has had any major illness or systemic infection (including COVID&#xD;
             [coronavirus disease] -19) within 4 weeks of the Screening Visit or has a clinically&#xD;
             relevant history or currently suffering from any disease or condition that, in the&#xD;
             opinion of the Investigator, may affect the evaluation of the study product or place&#xD;
             the participant at undue risk. Participant has liver function tests &gt;1.1x the upper&#xD;
             limit of normal or any other abnormal laboratory test that the Investigator deems as&#xD;
             clinically significant.&#xD;
&#xD;
          -  Participant has human immunodeficiency virus (HIV), hepatitis B virus (HBV), or&#xD;
             hepatitis C virus (HCV) infection, a clinically relevant history of or current&#xD;
             evidence of abuse of alcohol or other drugs. Participant is currently a tobacco smoker&#xD;
             or was a tobacco smoker within 6 months of the Baseline Visit.&#xD;
&#xD;
          -  Participant has received any investigational product within 4 weeks or 5 half-lives of&#xD;
             the product, whichever is greater, prior to the Baseline Visit or is scheduled to&#xD;
             receive an investigational product (other than the study product) or is scheduled for&#xD;
             a medical procedure during the study period. Participant is taking probiotics.&#xD;
&#xD;
          -  Participant is taking any medications which are known cytochrome P450 3A (CYP3A) or&#xD;
             P-glycoprotein (Pgp) inhibitors/inducers or is currently using any medication that, in&#xD;
             the opinion of the Investigator, may affect the evaluation of the study product or&#xD;
             place the participant at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schwabe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland Clinical Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

